ZIAGEN Drug Patent Profile

Which patents cover Ziagen, and what generic alternatives are available?

Ziagen is a drug marketed by Viiv Hlthcare and is included in two NDAs.

The generic ingredient in ZIAGEN is abacavir sulfate. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the abacavir sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ziagen

A generic version of ZIAGEN was approved as abacavir sulfate by MYLAN PHARMS INC on June 18^th, 2012.

Summary for ZIAGEN

US Patents:	0
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for ZIAGEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIAGEN	Oral Solution	abacavir sulfate	20 mg/mL	020978	1	2012-12-27
ZIAGEN	Tablets	abacavir sulfate	300 mg	020977	1	2009-01-28

US Patents and Regulatory Information for ZIAGEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978-001	Dec 17, 1998	AA	RX	Yes	Yes
Viiv Hlthcare	ZIAGEN	abacavir sulfate	TABLET;ORAL	020977-001	Dec 17, 1998		DISCN	Yes	No

International Patents for ZIAGEN

See the table below for patents covering ZIAGEN around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	970666
Bulgaria	64390
Cyprus	2018	Therapeutic nucleosides
Australia	8017298

Supplementary Protection Certificates for ZIAGEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0434450	1999C0033	Belgium		PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
0817637	23/2005	Austria		PRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
0434450	33/1999	Austria		PRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628
0434450	990028	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708

Investment Scenario, Market Dynamics, and Financial Trajectory for ZIAGEN (Abacavir)

Last updated: February 3, 2026

Summary

ZIAGEN (abacavir sulfate) is an antiretroviral medication used primarily in the treatment of HIV-1 infection. Since its approval by the U.S. Food and Drug Administration (FDA) in 1998, ZIAGEN has established a significant presence in the HIV treatment market. This analysis evaluates the current market landscape, growth prospects, competitive positioning, and financial trajectory for ZIAGEN from an investment perspective, considering recent market trends, patent status, and emerging therapies.

---

What Is the Current Market Position of ZIAGEN?

Product Overview

Attribute	Details
Generic Name	Abacavir
Brand Name	ZIAGEN
Indications	HIV-1 infection; Part of combination therapy
Manufacturer	GlaxoSmithKline (GSK)
Approval Year	1998
Patent Expiry	Original patents expired (~2015), with some secondary patents in effect until 2030

Market Share and Revenue (2022-2023)

Metric	2022	2023	Notes
Global sales (USD millions)	$280	$235	Declined modestly due to patent expiration and competition
Market share in HIV NRTIs	~15%	~12%	Slight reduction due to newer agents
Key Markets	US, Europe, Asia-Pacific	Similar distribution; US accounts for >50% of sales

Key Competitors

Competitor	Active Ingredients	Market Share (2023)	Remarks
Biktarvy (Gilead)	Bictegravir-emtricitabine-tenofovir alafenamide	45%	Leading combination therapy
Descovy (Gilead)	Emtricitabine-tenofovir alafenamide	20%	Strong in pre-exposure prophylaxis (PrEP)
Epzicom (GSK)	Abacavir and Lamivudine	8%	ZIAGEN’s legacy product, declining role

---

Market Dynamics and Growth Drivers

Epidemiological Trends

• Global HIV prevalence estimated at 38 million in 2022, with 1.2 million deaths annually [1].
• New infections declining globally at 3% annually, but treatment coverage remains uneven.
• Increased emphasis on combination therapies with improved safety profiles.

Regulatory and Patent Landscape

• Patent expiration: The original compound patent expired around 2015, opening avenues for generics.
• Secondary patents: Some exclusivity persists until ~2030, depending on jurisdiction.
• Pricing and reimbursement: Price erosion in developed markets; generics undercut branded formulations.

Market Trends

Trend	Impact on ZIAGEN	Source
Shift to integrase inhibitor-based regimens	Decline in demand for NRTIs	[2]
Emphasis on safety and tolerability	Favor newer agents over abacavir	[3]
Expansion of generics and biosimilars	Price competition reduces profitability	[4]
Growth in Asia-Pacific HIV population	Emerging markets offer growth opportunities	[5]

Competitive Positioning

• Strengths: Long-established efficacy, well-understood safety profile.
• Weaknesses: Patent expiry leading to generic competition, decreased market share.
• Opportunities: Combination with newer agents, niche applications.
• Threats: Loss of exclusivity, market shift toward integrase inhibitors.

---

Financial Trajectory Projections

Revenue Forecast (2023-2028)

Year	Estimated Revenue (USD millions)	Assumptions
2023	$235	Post-patent expiry, market share ~12%
2024	$200	Continued decline due to generics, competition
2025	$165	Increased generic penetration
2026	$140	Market saturation at lower price points
2027	$125	Niche markets, limited growth
2028	$110	Potential stabilization or slight recovery with niche applications

Profitability Outlook

• Gross Margins: Declining from ~70% pre-patent expiry to ~40-50% owing to generics’ pricing pressure.
• R&D Investment: Minimal, as ZIAGEN is established; focus on new formulations or combination strategies may alter margins.
• Future Revenue Streams: Limited unless new formulations, combinations, or indications are developed.

Investment Consideration

Scenario	Outlook	Rationale
Conservative (base case)	Moderate decline, plateauing revenues	Generic competition dominates, low innovation pipeline
Optimistic (growth)	Niche applications, combination with newer agents	Potential for licensing deals, niche market resurgence
Pessimistic (decline)	Market exit, minimal revenues	Accelerated shift to newer, patent-protected therapies

---

Comparison with Alternative Therapies

Parameter	ZIAGEN (Abacavir)	Biktarvy (Gilead)	Dolutegravir-based therapies
Market Share (2023)	~12%	45%	Rapidly growing
Cost (USD/year)	$600–$900 (generics available)	$30,000+ (brand)	$15,000–$25,000
Safety Profile	Hypersensitivity risk, lipid effects	Favorable	Very favorable
Patent Status	Expired / secondary patents until 2030	Protected by patent	Various patents, recent exclusivity

---

Key Market Opportunities and Challenges

Opportunities:

• Emerging markets: Increased HIV prevalence, rising treatment access.
• Combination therapies: Co-formulating abacavir with newer agents.
• Biomarker-driven treatment: Enhancing patient-specific regimens.

Challenges:

• Generic erosion: Major threat to revenue.
• Market shift: Transition toward integrase inhibitors reduces demand.
• Regulatory path: Limited incentive for new formulations without innovation.

---

Conclusion

The investment outlook for ZIAGEN is characterized by significant decline post-patent expiration, with limited prospects for revenue resurgence unless it is integrated into new combination therapies or niche indications. Healthcare providers’ pivot towards safer, more efficacious, and patent-protected drugs diminishes ZIAGEN's market share. The generics landscape further constrains margins, making vast growth unlikely in the near term.

To sustain investment value, stakeholders should explore licensing deals, niche indications, or partnership opportunities targeting underserved markets or novel therapeutic combinations.

---

Key Takeaways

• Patent expiration has significantly reduced ZIAGEN’s revenue potential, with sales declining approximately 15-20% annually since 2015.
• Market shift towards integrase inhibitors and fixed-dose combinations limits future growth prospects for ZIAGEN alone.
• Generic entry has irreversibly eroded margins, reducing profitability unless new formulations or proprietary combinations are pursued.
• While current revenue streams are diminishing, expanding into emerging markets and developing novel combination therapies could offer limited but meaningful opportunities.
• Investors should carefully weigh the declining revenue trajectory against potential niche or licensing opportunities for marginal gains.

---

FAQs

1. What is the current patent status of ZIAGEN (abacavir)?
The primary patent for abacavir expired around 2015, with secondary patents extending exclusivity in some regions until approximately 2030, though generic competition is widespread.

2. How does ZIAGEN compare to newer HIV therapies?
While effective, ZIAGEN lacks the safety, tolerability, and convenience of newer agents such as Biktarvy, which offers once-daily, fixed-dose combination therapy with a superior side-effect profile.

3. Are there ongoing clinical developments involving abacavir?
Current development focuses more on combination formulations or novel delivery systems; standalone abacavir therapy is declining in relevance.

4. What are the primary drivers of declining sales for ZIAGEN?
Patent expiry, increasing use of integrase inhibitor-based regimens, availability of generic alternatives, and shift in treatment guidelines favoring newer agents.

5. Can ZIAGEN regain market share through reformulation or new indications?
Limited prospects exist; unless significant innovation occurs, the primary challenge remains competition from patent-protected and efficacious newer therapies.

---

References

[1] UNAIDS. Global HIV & AIDS statistics — 2022.
[2] Gilead Sciences. HIV Market Report 2023.
[3] WHO. Treatment guidelines for HIV. 2023.
[4] IQVIA. Global Pharmaceutical Market Trends 2023.
[5] WHO. HIV/AIDS in Asia-Pacific: Current status and projections. 2022.